In situ follicular lymphoma with a 14;18 translocation diagnosed by a multimodal approach

Sotomayor, Edgar A.; Shah, Inangati M.; Sanger, Warren G.; Mark, Hon Fong L.

doi:10.1016/j.yexmp.2007.03.001

Cited by 21 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The BCL2 ϩ cells are confined only to GCs and are not seen in the interfollicular region or elsewhere in the lymph node (Figures 2-3). 14,16,[20][21][22][23][24] There is also a spectrum in the number of the BCL2-positive cells identified within affected follicles ( Figure 3). Some of the involved GCs contain only a few positive cells in a background of BCL2-negative GC cells, whereas others are more extensively replaced by BCL2 ϩ cells (Figure 3).…”

Section: Intrafollicular Neoplasia/"in Situ" Fl: Diagnostic Criteriamentioning

confidence: 99%

See 1 more Smart Citation

How I treat: diagnosing and managing “in situ” lymphoma

Carbone

Santoro

2011

Blood

View full text Add to dashboard Cite

The "in situ" lymphomas are often incidental findings in an otherwise reactiveappearing lymph node. Notably, the risk of progression to clinically appreciable lymphoma is not yet fully known. The diagnosis of "in situ" lymphoma is feasible when immunohistochemical characterization is carried out and genetic abnormalities are assessed. "In situ" follicular lymphoma is characterized by the presence within the affected germinal centers of B cells that strongly express BCL2 protein, a finding that supports their neoplastic nature, in the absence of interfollicular infiltration. In "in situ" mantle cell lymphoma, the lymphoma involvement is typically limited to the inner mantle zone, where lymphoma cells are cyclin D1 IntroductionPathologists dealing with diagnostics of lymphomas, through the use of conventional methods and advanced technologies, on several occasions happen to come up against morphologic lesions that can presently be defined as "in situ" lymphomas. 1 In these lesions, the neoplastic cells proliferate "in situ" (ie, in the "place" that is occupied by the normal counterpart of the tumor cell, without invasion of surrounding structures). For example, in the case of "in situ" follicular lymphoma (FL), the accumulation of neoplastic cells is within the lymphoid follicles only. For these reasons, "in situ" lymphoma does not usually form a tumor; rather, the lesion follows the existing architecture of the involved lymphoid follicles of the lymph node or the lymphoid tissue. On such occasions, the pathologist could be reluctant to make a diagnosis of lymphoma because he or she probably would not be able, today, to answer the questions about the clinical meaning of "in situ" lymphoma. Both the pathologist and the clinician, indeed, could hardly answer the patients' direct/indirect questions: should I worry about it? If so, how worried should I be?The 2008 WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues has addressed the problem of "in situ" lesions among the early events in the evolution of lymphoid neoplasia. 2-4 "In situ" lesions have been recognized for both FL and mantle cell lymphoma (MCL). These "in situ" lesions are often incidental findings in an otherwise reactive-appearing lymph node, but the risk of progression to clinically appreciable lymphoma is not yet fully known for these focal lesions. 1 Therefore, it is not surprising that clear guidelines for diagnosis and management of these patients are still lacking.Given these considerations, in this paper we address this important and difficult topic that is increasingly recognized in the routine clinical practice. We discuss how to make a reliable and precise diagnosis of "in situ" lymphoma and when and how to treat the patient. The partnership between the pathologist and the clinician is crucial in the management of patients with these lesions that appear to have limited potential for histologic or clinical progression and for which clinical and therapeutic data are very limited. "In situ" lymphomas among the early events in th...

show abstract

Section: Intrafollicular Neoplasia/"in Situ" Fl: Diagnostic Criteriamentioning

confidence: 99%

“…on May 10, 2018. by guest www.bloodjournal.org From abnormalities are assessed. 24 The good quality of the tissue sample is unavoidable and is a "sine qua non" condition.…”

mentioning

confidence: 99%

How I treat: diagnosing and managing “in situ” lymphoma

Carbone

Santoro

2011

Blood

View full text Add to dashboard Cite

show abstract

“…Since then, a few case reports and a series of 13 cases have been described. [25][26][27][28][29][30] The differential diagnosis of FLIS includes partial involvement by FL (PFL), and one study concluded that PFL was associated with low-stage disease. 31 However, standardized criteria for the distinction of FLIS and PFL have not been applied routinely in the literature.…”

Section: Introductionmentioning

confidence: 99%

Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma

Jegalian

Éberlé

Pack

et al. 2011

Blood

141

143

View full text Add to dashboard Cite

“…Neoplastic cells of in situ follicular neoplasia are derived from germinal center B cells and display the genetic hallmark t(14;18) (q32;q21) (Sotomayor et al, 2007;Cheung et al, 2009). In situ hybridisation analysis for t(14;18) ( Fig.…”

Section: Geneticsmentioning

confidence: 99%